Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Cassarino MF, Ambrogio AG, Cassarino A, Terreni MR, Gentilini D, Sesta A, Cavagnini F, Losa M, Pecori Giraldi F. Gene expression profiling in human corticotroph tumours reveals distinct, neuroendocrine profiles. J Neuroendocrinol 2018;30:e12628. [PMID: 29920815 PMCID: PMC6175113 DOI: 10.1111/jne.12628] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/12/2017] [Revised: 06/11/2018] [Accepted: 06/14/2018] [Indexed: 12/15/2022]

For:	Cassarino MF, Ambrogio AG, Cassarino A, Terreni MR, Gentilini D, Sesta A, Cavagnini F, Losa M, Pecori Giraldi F. Gene expression profiling in human corticotroph tumours reveals distinct, neuroendocrine profiles. J Neuroendocrinol 2018;30:e12628. [PMID: 29920815 PMCID: PMC6175113 DOI: 10.1111/jne.12628] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/12/2017] [Revised: 06/11/2018] [Accepted: 06/14/2018] [Indexed: 12/15/2022]

Number

Cited by Other Article(s)

Buzdin AA, Heydarov RN, Golounina OO, Suntsova MV, Matrosova AV, Bondarenko EV, Roumiantsev SA, Sorokin MI, Kholodenko RV, Kholodenko IV, Chekhonin VP, Plaksina EV, Rozhinskaya LY, Melnichenko GA, Belaya ZE. Transcriptome-Wide Analysis of Pituitary and Ectopic Adrenocorticotropic Hormone-Secreting Tumors. Cancers (Basel) 2025;17:658. [PMID: 40002253 PMCID: PMC11852724 DOI: 10.3390/cancers17040658] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2024] [Revised: 01/22/2025] [Accepted: 02/12/2025] [Indexed: 02/27/2025] Open

Affiliation(s)

Anton A. Buzdin Endocrinology Research Center, Moscow 117036, Russia; (R.N.H.); (O.O.G.); (M.V.S.); (A.V.M.); (E.V.B.); (S.A.R.); (M.I.S.); (V.P.C.); (E.V.P.); (L.Y.R.); (G.A.M.); (Z.E.B.) Institute of Personalized Oncology, I.M. Sechenov First Moscow State Medical University, Moscow 119991, Russia Moscow Institute of Physics and Technology, Dolgoprudny 141701, Russia Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow 117997, Russia;
Rustam N. Heydarov Endocrinology Research Center, Moscow 117036, Russia; (R.N.H.); (O.O.G.); (M.V.S.); (A.V.M.); (E.V.B.); (S.A.R.); (M.I.S.); (V.P.C.); (E.V.P.); (L.Y.R.); (G.A.M.); (Z.E.B.) Institute of Personalized Oncology, I.M. Sechenov First Moscow State Medical University, Moscow 119991, Russia
Olga O. Golounina Endocrinology Research Center, Moscow 117036, Russia; (R.N.H.); (O.O.G.); (M.V.S.); (A.V.M.); (E.V.B.); (S.A.R.); (M.I.S.); (V.P.C.); (E.V.P.); (L.Y.R.); (G.A.M.); (Z.E.B.)
Maria V. Suntsova Endocrinology Research Center, Moscow 117036, Russia; (R.N.H.); (O.O.G.); (M.V.S.); (A.V.M.); (E.V.B.); (S.A.R.); (M.I.S.); (V.P.C.); (E.V.P.); (L.Y.R.); (G.A.M.); (Z.E.B.) Moscow Institute of Physics and Technology, Dolgoprudny 141701, Russia
Alina V. Matrosova Endocrinology Research Center, Moscow 117036, Russia; (R.N.H.); (O.O.G.); (M.V.S.); (A.V.M.); (E.V.B.); (S.A.R.); (M.I.S.); (V.P.C.); (E.V.P.); (L.Y.R.); (G.A.M.); (Z.E.B.) Institute of Personalized Oncology, I.M. Sechenov First Moscow State Medical University, Moscow 119991, Russia
Ekaterina V. Bondarenko Endocrinology Research Center, Moscow 117036, Russia; (R.N.H.); (O.O.G.); (M.V.S.); (A.V.M.); (E.V.B.); (S.A.R.); (M.I.S.); (V.P.C.); (E.V.P.); (L.Y.R.); (G.A.M.); (Z.E.B.)
Sergey A. Roumiantsev Endocrinology Research Center, Moscow 117036, Russia; (R.N.H.); (O.O.G.); (M.V.S.); (A.V.M.); (E.V.B.); (S.A.R.); (M.I.S.); (V.P.C.); (E.V.P.); (L.Y.R.); (G.A.M.); (Z.E.B.)
Maksim I. Sorokin Endocrinology Research Center, Moscow 117036, Russia; (R.N.H.); (O.O.G.); (M.V.S.); (A.V.M.); (E.V.B.); (S.A.R.); (M.I.S.); (V.P.C.); (E.V.P.); (L.Y.R.); (G.A.M.); (Z.E.B.) Oncobox LLC, Moscow 119991, Russia
Roman V. Kholodenko Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow 117997, Russia;
Irina V. Kholodenko Laboratory of Cell Biology, Orekhovich Institute of Biomedical Chemistry, Moscow 119121, Russia;
Vladimir P. Chekhonin Endocrinology Research Center, Moscow 117036, Russia; (R.N.H.); (O.O.G.); (M.V.S.); (A.V.M.); (E.V.B.); (S.A.R.); (M.I.S.); (V.P.C.); (E.V.P.); (L.Y.R.); (G.A.M.); (Z.E.B.)
Evgeniya V. Plaksina Endocrinology Research Center, Moscow 117036, Russia; (R.N.H.); (O.O.G.); (M.V.S.); (A.V.M.); (E.V.B.); (S.A.R.); (M.I.S.); (V.P.C.); (E.V.P.); (L.Y.R.); (G.A.M.); (Z.E.B.)
Liudmila Y. Rozhinskaya Endocrinology Research Center, Moscow 117036, Russia; (R.N.H.); (O.O.G.); (M.V.S.); (A.V.M.); (E.V.B.); (S.A.R.); (M.I.S.); (V.P.C.); (E.V.P.); (L.Y.R.); (G.A.M.); (Z.E.B.)
Galina A. Melnichenko Endocrinology Research Center, Moscow 117036, Russia; (R.N.H.); (O.O.G.); (M.V.S.); (A.V.M.); (E.V.B.); (S.A.R.); (M.I.S.); (V.P.C.); (E.V.P.); (L.Y.R.); (G.A.M.); (Z.E.B.)
Zhanna E. Belaya Endocrinology Research Center, Moscow 117036, Russia; (R.N.H.); (O.O.G.); (M.V.S.); (A.V.M.); (E.V.B.); (S.A.R.); (M.I.S.); (V.P.C.); (E.V.P.); (L.Y.R.); (G.A.M.); (Z.E.B.)

Collapse

Regazzo D, Avallone S, MacSweeney CP, Sergeev E, Howe D, Godwood A, Bennett KA, Brown AJH, Barnes M, Occhi G, Barbot M, Faggian D, Tropeano MP, Losa M, Lasio G, Scaroni C, Pecori Giraldi F. A novel somatostatin receptor ligand for human ACTH - and GH -secreting pituitary adenomas. Eur J Endocrinol 2024;190:K8-K16. [PMID: 38123488 DOI: 10.1093/ejendo/lvad171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/07/2023] [Revised: 11/11/2023] [Accepted: 12/04/2023] [Indexed: 12/23/2023]

Rebollar-Vega RG, Zuarth-Vázquez JM, Hernández-Ramírez LC. Clinical Spectrum of USP8 Pathogenic Variants in Cushing's Disease. Arch Med Res 2023;54:102899. [PMID: 37925320 DOI: 10.1016/j.arcmed.2023.102899] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2023] [Revised: 10/16/2023] [Accepted: 10/19/2023] [Indexed: 11/06/2023]

Banerjee A, Ray A, Barpanda A, Dash A, Gupta I, Nissa MU, Zhu H, Shah A, Duttagupta SP, Goel A, Srivastava S. Evaluation of autoantibody signatures in pituitary adenoma patients using human proteome arrays. Proteomics Clin Appl 2022;16:e2100111. [PMID: 35939377 DOI: 10.1002/prca.202100111] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2022] [Revised: 07/08/2022] [Accepted: 08/03/2022] [Indexed: 12/30/2022]

Regazzo D, Mondin A, Scaroni C, Occhi G, Barbot M. The Role of Glucocorticoid Receptor in the Pathophysiology of Pituitary Corticotroph Adenomas. Int J Mol Sci 2022;23:ijms23126469. [PMID: 35742910 PMCID: PMC9224504 DOI: 10.3390/ijms23126469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2022] [Revised: 06/06/2022] [Accepted: 06/08/2022] [Indexed: 11/17/2022] Open

Treppiedi D, Barbieri AM, Di Muro G, Marra G, Mangili F, Catalano R, Esposito E, Ferrante E, Serban AL, Locatelli M, Lania AG, Spada A, Arosio M, Peverelli E, Mantovani G. Genetic Profiling of a Cohort of Italian Patients with ACTH-Secreting Pituitary Tumors and Characterization of a Novel USP8 Gene Variant. Cancers (Basel) 2021;13:cancers13164022. [PMID: 34439178 PMCID: PMC8392476 DOI: 10.3390/cancers13164022] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2021] [Revised: 06/17/2021] [Accepted: 08/07/2021] [Indexed: 12/18/2022] Open

Abstract

Simple Summary

Cushing’s Disease (CD) is a rare but severe endocrine disorder due to an adrenocorticotropic hormone (ACTH)-secreting pituitary tumor, and pathogenetics remained a puzzling issue for a long time. The recent identification of somatic mutations in the 14-3-3 protein binding motif of ubiquitin specific peptidase 8 gene (USP8), present in a consistent subgroup of ACTH-secreting pituitary tumors, have represented a major advance in the understanding of CD pathogenesis. In our cohort of 60 patients we found an incidence of 11.7% of USP8 recurrent somatic mutations whereas a novel USP8 variant (G664R) located upstream the canonical USP8 mutational hotspot was identified in one case. This alteration has never been reported by previous records. The present study provides USP8 G664R variant in vitro functional characterization in AtT-20 cells and demonstrates its possible implication in ACTH-secreting tumor pathogenesis, contributing to enlarge the genetic landscape of CD.

Abstract

Cushing’s Disease (CD) is a rare condition characterized by an overproduction of ACTH by an ACTH-secreting pituitary tumor, resulting in an excess of cortisol release by the adrenal glands. Somatic mutations in the deubiquitinases USP8 and USP48, and in BRAF genes, have been reported in a subset of patients affected by CD. The aim of this study was to characterize the genetic profile of a cohort of 60 patients with ACTH-secreting tumors, searching for somatic mutations in USP8, USP48, and BRAF hotspot regions. Seven patients were found to carry USP8 somatic mutations in the well-characterized 14-3-3 protein binding motif (n = 5 P720R, n = 1 P720Q, n = 1 S718del); 2 patients were mutated in USP48 (M415I); no mutation was identified in BRAF. In addition, a novel USP8 variant, G664R, located in exon 14, upstream of the 14-3-3 protein binding motif, was identified in 1 patient. Functional characterization of USP8 G664R variant was performed in murine corticotroph tumor AtT-20 cells. Transient transfection with the USP8 G664R variant resulted in a significant increase of ACTH release and cell proliferation (+114.5 ± 53.6% and +28.3 ± 2.6% vs. empty vector transfected cells, p < 0.05, respectively). Notably, USP8 proteolytic cleavage was enhanced in AtT-20 cells transfected with G664R USP8 (1.86 ± 0.58–fold increase of N-terminal USP8 fragment, vs. WT USP8, p < 0.05). Surprisingly, in situ Proximity Ligation Assay (PLA) experiments showed a significant reduction of PLA positive spots, indicating USP8/14-3-3 proteins colocalization, in G664R USP8 transfected cells with respect to WT USP8 transfected cells (−47.9 ± 6.6%, vs. WT USP8, p < 0.001). No significant difference in terms of ACTH secretion, cell proliferation and USP8 proteolytic cleavage, and 14-3-3 proteins interaction was observed between G664R USP8 and S718del USP8 transfected cells. Immunofluorescence experiments showed that, contrary to S718del USP8 but similarly to WT USP8 and other USP8 mutants, G664R USP8 displays an exclusive cytoplasmic localization. In conclusion, somatic mutations were found in USP8 (13.3% vs. 36.5% incidence of all published mutations) and USP48 (3.3% vs. 13.3% incidence) hotspot regions. A novel USP8 variant was identified in a CD patient, and in vitro functional studies in AtT-20 cells suggested that this somatic variant might be clinically relevant in ACTH-secreting tumor pathogenesis, expanding the characterization of USP8 functional domains.

Collapse

Affiliation(s)

Donatella Treppiedi Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy; (D.T.); (A.M.B.); (G.D.M.); (G.M.); (F.M.); (R.C.); (E.E.); (A.S.); (M.A.); (G.M.)
Anna Maria Barbieri Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy; (D.T.); (A.M.B.); (G.D.M.); (G.M.); (F.M.); (R.C.); (E.E.); (A.S.); (M.A.); (G.M.)
Genesio Di Muro Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy; (D.T.); (A.M.B.); (G.D.M.); (G.M.); (F.M.); (R.C.); (E.E.); (A.S.); (M.A.); (G.M.)
Giusy Marra Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy; (D.T.); (A.M.B.); (G.D.M.); (G.M.); (F.M.); (R.C.); (E.E.); (A.S.); (M.A.); (G.M.)
Federica Mangili Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy; (D.T.); (A.M.B.); (G.D.M.); (G.M.); (F.M.); (R.C.); (E.E.); (A.S.); (M.A.); (G.M.)
Rosa Catalano Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy; (D.T.); (A.M.B.); (G.D.M.); (G.M.); (F.M.); (R.C.); (E.E.); (A.S.); (M.A.); (G.M.)
Emanuela Esposito Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy; (D.T.); (A.M.B.); (G.D.M.); (G.M.); (F.M.); (R.C.); (E.E.); (A.S.); (M.A.); (G.M.)
Emanuele Ferrante Endocrinology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy; (E.F.); (A.L.S.)
Andreea Liliana Serban Endocrinology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy; (E.F.); (A.L.S.)
Marco Locatelli Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy; Neurosurgery Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy
Andrea Gerardo Lania Endocrinology, Diabetology and Medical Andrology Unit, Humanitas Clinical and Research Center, IRCCS, 20089 Rozzano, Italy; Department of Biomedical Sciences, Humanitas University, 20089 Rozzano, Italy
Anna Spada Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy; (D.T.); (A.M.B.); (G.D.M.); (G.M.); (F.M.); (R.C.); (E.E.); (A.S.); (M.A.); (G.M.)
Maura Arosio Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy; (D.T.); (A.M.B.); (G.D.M.); (G.M.); (F.M.); (R.C.); (E.E.); (A.S.); (M.A.); (G.M.) Endocrinology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy; (E.F.); (A.L.S.)
Erika Peverelli Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy; (D.T.); (A.M.B.); (G.D.M.); (G.M.); (F.M.); (R.C.); (E.E.); (A.S.); (M.A.); (G.M.) Correspondence: ; Tel.: +39-02-55033512
Giovanna Mantovani Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy; (D.T.); (A.M.B.); (G.D.M.); (G.M.); (F.M.); (R.C.); (E.E.); (A.S.); (M.A.); (G.M.) Endocrinology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy; (E.F.); (A.L.S.)

Collapse

Large Scale Molecular Studies of Pituitary Neuroendocrine Tumors: Novel Markers, Mechanisms and Translational Perspectives. Cancers (Basel) 2021;13:cancers13061395. [PMID: 33808624 PMCID: PMC8003417 DOI: 10.3390/cancers13061395] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2021] [Revised: 02/28/2021] [Accepted: 03/16/2021] [Indexed: 02/07/2023] Open

Abstract

Simple Summary

Pituitary neuroendocrine tumors are non-cancerous tumors of the pituitary gland, that may overproduce hormones leading to serious health conditions or due to tumor size cause chronic headache, vertigo or visual impairment. In recent years pituitary neuroendocrine tumors are studied with the latest molecular biology methods that simultaneously investigate a large number of factors to understand the mechanisms of how these tumors develop and how they could be diagnosed or treated. In this review article, we have studied literature reports, compiled information and described molecular factors that could affect the development and clinical characteristics of pituitary neuroendocrine tumors, discovered factors that overlap between several studies using large scale molecular analysis and interpreted the potential involvement of these factors in pituitary tumor development. Overall, this study provides a valuable resource for understanding the biology of pituitary neuroendocrine tumors.

Abstract

Pituitary neuroendocrine tumors (PitNETs) are non-metastatic neoplasms of the pituitary, which overproduce hormones leading to systemic disorders, or tumor mass effects causing headaches, vertigo or visual impairment. Recently, PitNETs have been investigated in large scale (exome and genome) molecular analyses (transcriptome microarrays and sequencing), to uncover novel markers. We performed a literature analysis on these studies to summarize the research data and extrapolate overlapping gene candidates, biomarkers, and molecular mechanisms. We observed a tendency in samples with driver mutations (GNAS, USP8) to have a smaller overall mutational rate, suggesting driver-promoted tumorigenesis, potentially changing transcriptome profiles in tumors. However, direct links from drivers to signaling pathways altered in PitNETs (Notch, Wnt, TGF-β, and cell cycle regulators) require further investigation. Modern technologies have also identified circulating nucleic acids, and pinpointed these as novel PitNET markers, i.e., miR-143-3p, miR-16-5p, miR-145-5p, and let-7g-5p, therefore these molecules must be investigated in the future translational studies. Overall, large-scale molecular studies have provided key insight into the molecular mechanisms behind PitNET pathogenesis, highlighting previously reported molecular markers, bringing new candidates into the research field, and reapplying traditional perspectives to newly discovered molecular mechanisms.

Collapse

Srirangam Nadhamuni V, Korbonits M. Novel Insights into Pituitary Tumorigenesis: Genetic and Epigenetic Mechanisms. Endocr Rev 2020;41:bnaa006. [PMID: 32201880 PMCID: PMC7441741 DOI: 10.1210/endrev/bnaa006] [Citation(s) in RCA: 59] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/20/2019] [Accepted: 03/19/2020] [Indexed: 02/08/2023]

Distinct Pattern of Endoplasmic Reticulum Protein Processing and Extracellular Matrix Proteins in Functioning and Silent Corticotroph Pituitary Adenomas. Cancers (Basel) 2020;12:cancers12102980. [PMID: 33066652 PMCID: PMC7650558 DOI: 10.3390/cancers12102980] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2020] [Revised: 09/30/2020] [Accepted: 10/05/2020] [Indexed: 12/30/2022] Open

Abstract

Simple Summary

Corticotroph pituitary adenomas present a spectrum of functionality regarding hormonal production, ranging from functioning to silent tumors. Moreover, they show different invasiveness and recurrent behavior profiles, the silent being considered an aggressive type of adenomas. Through analyses of global transcriptome and proteome, we show that both groups expressed genes and protein related to protein synthesis and vesicular transport, and present a distinct pattern of collagen/ extracellular matrix proteins. Endoplasmic reticulum protein processing is a key factor for hormone production in functioning corticotroph adenomas. Furthermore, a distinct cell adhesion profile in silent corticotroph adenomas may explain the aggressive behavior. Together, our findings shed light on the different repertoires of activated signaling pathways in corticotroph pituitary adenomas and may reveal new potential medical targets.

Abstract

Functioning (FCA) and silent corticotroph (SCA) pituitary adenomas act differently from a clinical perspective, despite both subtypes showing positive TBX19 (TPIT) and/or adrenocorticotropic hormone (ACTH) staining by immunohistochemistry. They are challenging to treat, the former due to functional ACTH production and consequently hypercortisolemia, and the latter due to invasive and recurrent behavior. Moreover, the molecular mechanisms behind their distinct behavior are not clear. We investigated global transcriptome and proteome changes in order to identify signaling pathways that can explain FCA and SCA differences (e.g., hormone production vs. aggressive growth). In the transcriptomic study, cluster analyses of differentially expressed genes revealed two distinct groups in accordance with clinical and histological classification. However, in the proteomic study, a greater degree of heterogeneity within the SCA group was found. Genes and proteins related to protein synthesis and vesicular transport were expressed by both adenoma groups, although different types and a distinct pattern of collagen/extracellular matrix proteins were presented by each group. Moreover, several genes related to endoplasmic reticulum protein processing were overexpressed in the FCA group. Together, our findings shed light on the different repertoires of activated signaling pathways in corticotroph adenomas, namely, the increased protein processing capacity of FCA and a specific pattern of adhesion molecules that may play a role in the aggressiveness of SCA.

Collapse

Wang Z, Guo X, Gao L, Deng K, Lian W, Bao X, Feng M, Duan L, Zhu H, Xing B. The Immune Profile of Pituitary Adenomas and a Novel Immune Classification for Predicting Immunotherapy Responsiveness. J Clin Endocrinol Metab 2020;105:5870365. [PMID: 32652004 PMCID: PMC7413599 DOI: 10.1210/clinem/dgaa449] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/04/2020] [Accepted: 07/08/2020] [Indexed: 02/07/2023]

Affiliation(s)

Zihao Wang Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China Key Laboratory of Endocrinology of Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China China Pituitary Disease Registry Center, Beijing, P. R. China China Pituitary Adenoma Specialist Council, Beijing, P. R. China
Xiaopeng Guo Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China Key Laboratory of Endocrinology of Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China China Pituitary Disease Registry Center, Beijing, P. R. China China Pituitary Adenoma Specialist Council, Beijing, P. R. China
Lu Gao Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China Key Laboratory of Endocrinology of Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China China Pituitary Disease Registry Center, Beijing, P. R. China China Pituitary Adenoma Specialist Council, Beijing, P. R. China
Kan Deng Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China Key Laboratory of Endocrinology of Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China China Pituitary Disease Registry Center, Beijing, P. R. China China Pituitary Adenoma Specialist Council, Beijing, P. R. China
Wei Lian Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China Key Laboratory of Endocrinology of Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China China Pituitary Disease Registry Center, Beijing, P. R. China China Pituitary Adenoma Specialist Council, Beijing, P. R. China
Xinjie Bao Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China Key Laboratory of Endocrinology of Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China China Pituitary Disease Registry Center, Beijing, P. R. China China Pituitary Adenoma Specialist Council, Beijing, P. R. China
Ming Feng Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China Key Laboratory of Endocrinology of Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China China Pituitary Disease Registry Center, Beijing, P. R. China China Pituitary Adenoma Specialist Council, Beijing, P. R. China
Lian Duan Key Laboratory of Endocrinology of Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China China Pituitary Disease Registry Center, Beijing, P. R. China China Pituitary Adenoma Specialist Council, Beijing, P. R. China Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China
Huijuan Zhu Key Laboratory of Endocrinology of Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China China Pituitary Disease Registry Center, Beijing, P. R. China China Pituitary Adenoma Specialist Council, Beijing, P. R. China Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China
Bing Xing Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China Key Laboratory of Endocrinology of Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China China Pituitary Disease Registry Center, Beijing, P. R. China China Pituitary Adenoma Specialist Council, Beijing, P. R. China Correspondence and Reprint Requests: Bing Xing, Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 1 Shuaifuyuan, Dongcheng District, Beijing 100730, P. R. China. E-mail:

Collapse

Assessment of Coagulation Parameters in Women Affected by Endometriosis: Validation Study and Systematic Review of the Literature. Diagnostics (Basel) 2020;10:diagnostics10080567. [PMID: 32784640 PMCID: PMC7460223 DOI: 10.3390/diagnostics10080567] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2020] [Revised: 07/29/2020] [Accepted: 08/05/2020] [Indexed: 01/01/2023] Open

Pecori Giraldi F, Cassarino MF, Sesta A, Terreni M, Lasio G, Losa M. Sexual Dimorphism in Cellular and Molecular Features in Human ACTH-Secreting Pituitary Adenomas. Cancers (Basel) 2020;12:E669. [PMID: 32183012 PMCID: PMC7139870 DOI: 10.3390/cancers12030669] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2020] [Revised: 03/09/2020] [Accepted: 03/10/2020] [Indexed: 12/15/2022] Open

Castellnou S, Vasiljevic A, Lapras V, Raverot V, Alix E, Borson-Chazot F, Jouanneau E, Raverot G, Lasolle H. SST5 expression and USP8 mutation in functioning and silent corticotroph pituitary tumors. Endocr Connect 2020;9:EC-20-0035.R1. [PMID: 32101529 PMCID: PMC7077525 DOI: 10.1530/ec-20-0035] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/24/2020] [Accepted: 02/25/2020] [Indexed: 12/14/2022]

Affiliation(s)

Solène Castellnou Service d’Endocrinologie, Centre de Référence des Maladies Rares de l’Hypophyse HYPO, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France Université Lyon 1, Villeurbanne, France
Alexandre Vasiljevic Université Lyon 1, Villeurbanne, France Centre de Biologie et Pathologie Est, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France INSERM U1052, CNRS, UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France
Véronique Lapras Service de Radiologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France
Véronique Raverot Laboratoire d’Hormonologie, Centre de Biologie et Pathologie Est, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France
Eudeline Alix Département de Cytogénétique, Centre de Biologie et Pathologie Est, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France
Françoise Borson-Chazot Service d’Endocrinologie, Centre de Référence des Maladies Rares de l’Hypophyse HYPO, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France Université Lyon 1, Villeurbanne, France
Emmanuel Jouanneau Université Lyon 1, Villeurbanne, France INSERM U1052, CNRS, UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France Service de Neurochirurgie, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France
Gérald Raverot Service d’Endocrinologie, Centre de Référence des Maladies Rares de l’Hypophyse HYPO, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France Université Lyon 1, Villeurbanne, France INSERM U1052, CNRS, UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France
Hélène Lasolle Service d’Endocrinologie, Centre de Référence des Maladies Rares de l’Hypophyse HYPO, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France Université Lyon 1, Villeurbanne, France INSERM U1052, CNRS, UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France

Collapse

Hu J, Yin H, Li B, Yang H. Identification of Transcriptional Metabolic Dysregulation in Subtypes of Pituitary Adenoma by Integrated Bioinformatics Analysis. Diabetes Metab Syndr Obes 2019;12:2441-2451. [PMID: 31819570 PMCID: PMC6885545 DOI: 10.2147/dmso.s226056] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/05/2019] [Accepted: 11/06/2019] [Indexed: 12/13/2022] Open

Sesta A, Cassarino MF, Terreni M, Ambrogio AG, Libera L, Bardelli D, Lasio G, Losa M, Pecori Giraldi F. Ubiquitin-Specific Protease 8 Mutant Corticotrope Adenomas Present Unique Secretory and Molecular Features and Shed Light on the Role of Ubiquitylation on ACTH Processing. Neuroendocrinology 2019;110:119-129. [PMID: 31280266 PMCID: PMC6979434 DOI: 10.1159/000500688] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/14/2019] [Revised: 05/01/2019] [Accepted: 05/01/2019] [Indexed: 12/19/2022]

Abstract

BACKGROUND

Somatic mutations in the ubiquitin-specific protease 8 (USP8) gene have recently been shown to occur in ACTH-secreting pituitary adenomas, thus calling attention to the ubiquitin system in corticotrope adenomas.

OBJECTIVES

Assess the consequences of USP8 mutations and establish the role of ubiquitin on ACTH turnover in human ACTH-secreting pituitary adenomas.

METHODS

USP8 mutation status was established in 126 ACTH-secreting adenomas. Differences in ACTH secretion and POMC expression from adenoma primary cultures and in microarray gene expression profiles from archival specimens were sought according to USP8 sequence. Ubiquitin/ACTH coimmunoprecipitation and incubation with MG132, a proteasome inhibitor, were performed in order to establish whether ubiquitin plays a role in POMC/ACTH degradation in corticotrope adenomas.

RESULTS

USP8 mutations were identified in 29 adenomas (23%). Adenomas presenting USP8 mutations secreted greater amounts of ACTH and expressed POMC at higher levels compared to USP wild-type specimens. USP8 mutant adenomas were also more sensitive to modulation by CRH and dexamethasone in vitro. At microarray analysis, genes associated with endosomal protein degradation and membrane components were downregulated in USP8 mutant adenomas as were AVPR1B, IL11RA, and PITX2. Inhibition of the ubiquitin-proteasome pathway increased ACTH secretion and POMC itself proved a target of ubiquitylation, independently of USP8 sequence status.

CONCLUSIONS

Our study has shown that USP8 mutant ACTH-secreting adenomas present a more "typical" corticotrope phenotype and reduced expression of several genes associated with protein degradation. Further, ubiquitylation is directly involved in intracellular ACTH turnover, suggesting that the ubiquitin-proteasome system may represent a target for treatment of human ACTH-secreting adenomas.

Collapse

Losa M, Mortini P, Pagnano A, Detomas M, Cassarino MF, Pecori Giraldi F. Clinical characteristics and surgical outcome in USP8-mutated human adrenocorticotropic hormone-secreting pituitary adenomas. Endocrine 2019;63:240-246. [PMID: 30315484 DOI: 10.1007/s12020-018-1776-0] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/05/2018] [Accepted: 09/24/2018] [Indexed: 01/24/2023]

Cassarino MF, Ambrogio AG, Cassarino A, Terreni MR, Gentilini D, Sesta A, Cavagnini F, Losa M, Pecori Giraldi F. Gene expression profiling in human corticotroph tumours reveals distinct, neuroendocrine profiles. J Neuroendocrinol 2018;30:e12628. [PMID: 29920815 PMCID: PMC6175113 DOI: 10.1111/jne.12628] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/12/2017] [Revised: 06/11/2018] [Accepted: 06/14/2018] [Indexed: 12/15/2022]